it notion is supported by the observation the SAR for aer

lenalidomide, a chemotherapeutic agent FDA-APPROVED for treating multiple Afatinib myeloma, is proven to have many immunomodulatory results, including activation of NK cell cytotoxicity, development of T cell function, and suppression of growth and Treg function. 77, 78 Like other agencies of its course, lenalidomide is also anti-apoptotic and anti-angiogenic, and may reduce the potential of tumors. 79, 80 There's growing interest in the potential therapeutic advantages of regimens combining cancer vaccines plus standard of care chemotherapy. Nevertheless, there are lots of important considerations. First, using vaccine and chemotherapy early in the disease process might have significantly different clinical results than administering vaccine after multiple chemotherapeutic regimens in advanced stage disease, if the immune system is probably impaired. Minute, not all chemotherapeutic agents are suitable for vaccine. And next, when Lymph node used in combination with chemotherapy, the time of vaccine administration could be extremely important. Accumulating preclinical evidence of the effects of chemotherapy presents new choices for combining chemotherapy with vaccine to create effective antitumor immunity in the clinical setting. A few adult platforms already are being used clinically. Further clinical studies will be needed to optimize the utilization of these and other combination regimens. Within the last decade, utilization of specific SMIs for the treatment of many tumor types has increased. 81 The major difference between standard chemotherapeutic agents and SMIs is the fact that the previous curb rapidly proliferating cells while the latter target specific proteinprotein interactions, checkpoint inhibitors including growth facets and their receptors. 82 Compared to standard chemotherapy, focused therapy with SMIs gets the advantage of modulating specific cellular pathways which can be important for cyst biology, along with the advantages of increased effectiveness and decreased toxicity. Additionally there are many potential advantages of combining SMIs with immunotherapy. Immune activation can be selectively increased by some SMIs by inhibiting immune suppressor cells such as Tregs and MDSCs and/or by causing immune effector cells such as DCs and CTLs. SMIs will make tumor cells more vunerable to immune mediated killing by increasing tumor certain antigen presentation and/or FAS mediated killing. Also, the synergistic effect of combining SMIs with vaccine may justify the government of SMIs at a lower dose, further decreasing the potential for accumulation. Achieving an optimal outcome when mixing immunotherapy and SMIs involves determining the right timing of vaccine administration and SMI treatment. The most effective combination agenda must end up in powerful immune excitement against TAAs, with little or no toxicity against immune effector cells.